FLXN Flexion Therapeutics Inc.

14.87
+0.21  (+1%)
Previous Close 14.66
Open 14.62
Price To Book 3.85
Market Cap 562929679
Shares 37,856,737
Volume 237,241
Short Ratio
Av. Daily Volume 701,707

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation of enrolment announced January 2, 2019. To be completed in 2020.
Zilretta
Osteoarthritis of the hip
Approval announced October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes
sNDA filing announced December 17, 2018.
Zilretta - FX006 repeat
Osteoarthritis of the knee
Top-line safety data due 2Q 2018.
Zilretta - FX006
Osteoarthritis of the knee

Latest News

  1. Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy
  2. Here's Why Flexion Therapeutics Rose 29.8% in January
  3. Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12
  4. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  5. Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality — Fundamental Analysis, Key Performance Indications
  6. Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
  7. The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO
  8. Flexion shares plummet after weak revenue guidance
  9. Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019
  10. Raymond James: Flexion Therapeutics Estimates Are A Stretch
  11. Flexion Starts Phase III Enrollment on Zilretta for Hip OA
  12. Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study
  13. Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019
  14. Flexion Therapeutics Submits Supplemental New Drug Application (sNDA) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
  15. Here's Why Flexion Therapeutics Jumped 20.5% in November
  16. 2 Small Biotech Stocks That Insiders Are Buying
  17. Flexion Therapeutics Inc (NASDAQ:FLXN): What Does Its Beta Value Mean For Your Portfolio?
  18. New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018